

INCLUSION Global Study Details

Gilead, Unitaid and the US National Institutes of Health are funding 36 ongoing studies to investigate implementation outcomes, rapid initiation and real-life use of injectable lenacapavir (LEN) for PrEP in 9 countries. Gilead's INCLUSION program (INCLUSION Global in Africa and Asia and INCLUSION-US in the United States) accounts for 26 of these studies. This table provides details on the INCLUSION Global projects planned for 2026-2028 in 7 LEN early adopter countries.

Project	Country	Implementer	Population	Participants
Feasibility, Acceptability and Retention on Lenacapavir PrEP as Part of a Comprehensive Prevention Program for Pregnant and Breast Feeding Women and Adolescent Girls and Young Women: An Implementation Study in Eswatini		Baylor Children's Foundation Eswatini	AGYW, PLP	400
Delivering LEN-PrEP at Scale for Pregnant and Postpartum Women in Kenyan Maternal and Child Health Clinics		Kenyatta National Hospital	PLP	3,200
PINALAPIT: Co-Implementation and Comparative Evaluation of Twice-Yearly Lenacapavir and Oral PrEP across Government- and CBO-led HIV Care Facilities in Urban and Rural Health Settings in the Philippines		Sustained Health Initiatives of the Philippines (SHIP)	KPs (MSM, TGW, PUID), YA	600
Pre-Pre-Pre-Post Study: A Mixed-Methods Observational Study to Assess the Uptake, Acceptability, Preferences and Feasibility of Providing LEN Postnatally for HIV Prevention Among South African Breastfeeding People		The Aurum Institute	PLP	150
Evaluating the Implementation Outcomes of a Peer-Enhanced, Digitally Enabled, Public Sector Mobile Lenacapavir Service Delivery Model for Female Sex Workers (Link2LEN) in Ekurhuleni Health District, South Africa		Wits Health Consortium / Wits RHI, University of the Witwatersrand, Johannesburg	FSW	1,000
Scaling Lenacapavir: A Pragmatic Evaluation of Integrating Twice-Yearly Injectable PrEP into Maternal and Reproductive Health Services for AGYW in Uganda		Makerere University - Johns Hopkins University Research Collaboration	AGYW	800
Health Access for Lenacapavir Outcomes (HALO) Study		Ciheb Zambia	AGYW, KP (FSW, MSM, PUID)	420
Mentor-Mothers and Peer-Assisted Implementation Models for Accelerating LENAcapavir PrEP Uptake among Pregnant and Breastfeeding Women in Zambia (MAMA-LENA) Study		University Teaching Hospital	PLP	652
Optimizing Timely Return for Lenacapavir Injections: A Hybrid Type 3 Study of Low-Burden Touchpoint Implementation Strategies in Zimbabwe		Zimbabwe Ministry of Health and Child Care / Pangaea Zimbabwe	All	544
Developing and Evaluating Pharmacy-Based Provision of Lenacapavir Injection for PrEP Among People at High Risk of HIV Including Female Sex Workers in Zimbabwe: A Mixed-Methods Study		CeSHHAR Zimbabwe	FSW	522

AGYW: Adolescent Girls and Young Women; FSW: Female Sex Workers; KP: Key Populations; MSM: Men Who Have Sex With Men; PLP: Pregnant and Lactating People; PUID: People Who Use and Inject Drugs; TGW: Transgender Women; YA: Young Adults

For more details on all ongoing LEN implementation studies, [see our map](#) and visit the [integrated study dashboard](#)